vs
伯乐实验室（BIO）与微芯科技（MCHP）财务数据对比。点击上方公司名可切换其他公司
微芯科技的季度营收约是伯乐实验室的1.7倍（$1.2B vs $693.2M），伯乐实验室净利率更高（103.9% vs 5.3%，领先98.6%），微芯科技同比增速更快（15.6% vs 3.9%），微芯科技自由现金流更多（$318.9M vs $119.1M），过去两年伯乐实验室的营收复合增速更高（6.5% vs -5.4%）
美国伯乐实验室是深耕生命科学研究与临床诊断领域的专业技术产品开发商及制造商，1952年由加州大学伯克利分校校友施瓦茨夫妇在伯克利创立，总部位于加州赫拉克勒斯，业务网络覆盖全球。
微芯科技（Microchip Technology）是美国知名上市半导体企业，主营微控制器、混合信号芯片、模拟芯片及闪存知识产权（Flash-IP）相关集成电路的研发、生产与销售，产品覆盖工业控制、汽车电子、消费电子、物联网等众多领域，在全球半导体细分市场拥有领先地位。
BIO vs MCHP — 直观对比
营收规模更大
MCHP
是对方的1.7倍
$693.2M
营收增速更快
MCHP
高出11.7%
3.9%
净利率更高
BIO
高出98.6%
5.3%
自由现金流更多
MCHP
多$199.8M
$119.1M
两年增速更快
BIO
近两年复合增速
-5.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $693.2M | $1.2B |
| 净利润 | $720.0M | $62.7M |
| 毛利率 | 49.8% | 59.6% |
| 营业利润率 | -17.2% | 12.8% |
| 净利率 | 103.9% | 5.3% |
| 营收同比 | 3.9% | 15.6% |
| 净利润同比 | 200.6% | 217.0% |
| 每股收益（稀释后） | $26.59 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOMCHP
| Q4 25 | $693.2M | $1.2B | ||
| Q3 25 | $653.0M | $1.1B | ||
| Q2 25 | $651.6M | $1.1B | ||
| Q1 25 | $585.4M | $970.5M | ||
| Q4 24 | $667.5M | $1.0B | ||
| Q3 24 | $649.7M | $1.2B | ||
| Q2 24 | $638.5M | $1.2B | ||
| Q1 24 | $610.8M | $1.3B |
净利润BIOMCHP
| Q4 25 | $720.0M | $62.7M | ||
| Q3 25 | $-341.9M | $41.7M | ||
| Q2 25 | $317.8M | $-18.6M | ||
| Q1 25 | $64.0M | $-154.6M | ||
| Q4 24 | $-715.8M | $-53.6M | ||
| Q3 24 | $653.2M | $78.4M | ||
| Q2 24 | $-2.2B | $129.3M | ||
| Q1 24 | $383.9M | $154.7M |
毛利率BIOMCHP
| Q4 25 | 49.8% | 59.6% | ||
| Q3 25 | 52.6% | 55.9% | ||
| Q2 25 | 53.0% | 53.6% | ||
| Q1 25 | 52.3% | 51.6% | ||
| Q4 24 | 51.2% | 54.7% | ||
| Q3 24 | 54.8% | 57.4% | ||
| Q2 24 | 55.6% | 59.4% | ||
| Q1 24 | 53.4% | 59.6% |
营业利润率BIOMCHP
| Q4 25 | -17.2% | 12.8% | ||
| Q3 25 | 10.0% | 7.8% | ||
| Q2 25 | 11.8% | 3.0% | ||
| Q1 25 | 4.0% | -10.3% | ||
| Q4 24 | 8.7% | 3.0% | ||
| Q3 24 | 9.9% | 12.6% | ||
| Q2 24 | 15.9% | 17.7% | ||
| Q1 24 | 7.3% | 19.1% |
净利率BIOMCHP
| Q4 25 | 103.9% | 5.3% | ||
| Q3 25 | -52.4% | 3.7% | ||
| Q2 25 | 48.8% | -1.7% | ||
| Q1 25 | 10.9% | -15.9% | ||
| Q4 24 | -107.2% | -5.2% | ||
| Q3 24 | 100.5% | 6.7% | ||
| Q2 24 | -339.2% | 10.4% | ||
| Q1 24 | 62.9% | 11.7% |
每股收益（稀释后）BIOMCHP
| Q4 25 | $26.59 | $0.06 | ||
| Q3 25 | $-12.70 | $0.03 | ||
| Q2 25 | $11.67 | $-0.09 | ||
| Q1 25 | $2.29 | $-0.29 | ||
| Q4 24 | $-25.89 | $-0.10 | ||
| Q3 24 | $23.34 | $0.14 | ||
| Q2 24 | $-76.26 | $0.24 | ||
| Q1 24 | $13.45 | $0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $250.7M |
| 总债务越低越好 | $1.2B | $5.4B |
| 股东权益账面价值 | $7.5B | $6.6B |
| 总资产 | $10.6B | $14.3B |
| 负债/权益比越低杠杆越低 | 0.16× | 0.82× |
8季度趋势，按日历期对齐
现金及短期投资BIOMCHP
| Q4 25 | $1.5B | $250.7M | ||
| Q3 25 | $1.4B | $236.8M | ||
| Q2 25 | $1.4B | $566.5M | ||
| Q1 25 | $1.7B | $771.7M | ||
| Q4 24 | $1.7B | $586.0M | ||
| Q3 24 | $1.6B | $286.1M | ||
| Q2 24 | $1.6B | $315.1M | ||
| Q1 24 | $1.6B | $319.7M |
总债务BIOMCHP
| Q4 25 | $1.2B | $5.4B | ||
| Q3 25 | $1.2B | $5.4B | ||
| Q2 25 | — | $5.5B | ||
| Q1 25 | — | $5.6B | ||
| Q4 24 | $1.2B | $6.7B | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.2B | ||
| Q1 24 | — | $6.0B |
股东权益BIOMCHP
| Q4 25 | $7.5B | $6.6B | ||
| Q3 25 | $6.7B | $6.7B | ||
| Q2 25 | $7.1B | $6.9B | ||
| Q1 25 | $6.7B | $7.1B | ||
| Q4 24 | $6.6B | $6.0B | ||
| Q3 24 | $7.5B | $6.3B | ||
| Q2 24 | $6.8B | $6.4B | ||
| Q1 24 | $9.1B | $6.7B |
总资产BIOMCHP
| Q4 25 | $10.6B | $14.3B | ||
| Q3 25 | $9.7B | $14.5B | ||
| Q2 25 | $10.2B | $15.0B | ||
| Q1 25 | $9.5B | $15.4B | ||
| Q4 24 | $9.4B | $15.6B | ||
| Q3 24 | $10.6B | $15.6B | ||
| Q2 24 | $9.7B | $15.8B | ||
| Q1 24 | $12.6B | $15.9B |
负债/权益比BIOMCHP
| Q4 25 | 0.16× | 0.82× | ||
| Q3 25 | 0.18× | 0.80× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | 0.18× | 1.12× | ||
| Q3 24 | — | 1.02× | ||
| Q2 24 | — | 0.96× | ||
| Q1 24 | — | 0.90× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.9M | $341.4M |
| 自由现金流经营现金流 - 资本支出 | $119.1M | $318.9M |
| 自由现金流率自由现金流/营收 | 17.2% | 26.9% |
| 资本支出强度资本支出/营收 | 6.6% | 1.9% |
| 现金转化率经营现金流/净利润 | 0.23× | 5.44× |
| 过去12个月自由现金流最近4个季度 | $374.6M | $819.9M |
8季度趋势，按日历期对齐
经营现金流BIOMCHP
| Q4 25 | $164.9M | $341.4M | ||
| Q3 25 | $120.9M | $88.1M | ||
| Q2 25 | $116.5M | $275.6M | ||
| Q1 25 | $129.9M | $205.9M | ||
| Q4 24 | $124.2M | $271.5M | ||
| Q3 24 | $163.6M | $43.6M | ||
| Q2 24 | $97.6M | $377.1M | ||
| Q1 24 | $69.8M | $430.0M |
自由现金流BIOMCHP
| Q4 25 | $119.1M | $318.9M | ||
| Q3 25 | $89.2M | $51.6M | ||
| Q2 25 | $70.8M | $257.7M | ||
| Q1 25 | $95.5M | $191.7M | ||
| Q4 24 | $81.2M | $253.4M | ||
| Q3 24 | $123.4M | $22.8M | ||
| Q2 24 | $55.4M | $304.2M | ||
| Q1 24 | $29.6M | $389.9M |
自由现金流率BIOMCHP
| Q4 25 | 17.2% | 26.9% | ||
| Q3 25 | 13.7% | 4.5% | ||
| Q2 25 | 10.9% | 24.0% | ||
| Q1 25 | 16.3% | 19.8% | ||
| Q4 24 | 12.2% | 24.7% | ||
| Q3 24 | 19.0% | 2.0% | ||
| Q2 24 | 8.7% | 24.5% | ||
| Q1 24 | 4.8% | 29.4% |
资本支出强度BIOMCHP
| Q4 25 | 6.6% | 1.9% | ||
| Q3 25 | 4.9% | 3.2% | ||
| Q2 25 | 7.0% | 1.7% | ||
| Q1 25 | 5.9% | 1.5% | ||
| Q4 24 | 6.4% | 1.8% | ||
| Q3 24 | 6.2% | 1.8% | ||
| Q2 24 | 6.6% | 5.9% | ||
| Q1 24 | 6.6% | 3.0% |
现金转化率BIOMCHP
| Q4 25 | 0.23× | 5.44× | ||
| Q3 25 | — | 2.11× | ||
| Q2 25 | 0.37× | — | ||
| Q1 25 | 2.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.25× | 0.56× | ||
| Q2 24 | — | 2.92× | ||
| Q1 24 | 0.18× | 2.78× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
MCHP
| Mixed Signal Microcontrollers | $586.5M | 49% |
| Analog | $322.9M | 27% |
| Other Product Line | $276.6M | 23% |
